

J Herrstedt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6627781/publications.pdf>

Version: 2024-02-01

35
papers

2,530
citations

471061

17
h-index

377514

34
g-index

35
all docs

35
docs citations

35
times ranked

3790
citing authors

#	ARTICLE	IF	CITATIONS
1	The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer – a population-based cross-sectional study. <i>Acta Oncologica</i> , 2022, 61, 363-370.	0.8	1
2	Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 1862.	1.0	2
3	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. <i>Cancers</i> , 2022, 14, 1682.	1.7	2
4	Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes. <i>Drugs and Aging</i> , 2022, 39, 1-21.	1.3	10
5	Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries. <i>ESMO Open</i> , 2021, 6, 100111.	2.0	13
6	The impact of comprehensive geriatric assessment for optimal treatment of older patients with cancer: A randomized parallel-group clinical trial. <i>Journal of Geriatric Oncology</i> , 2020, 11, 488-495.	0.5	22
7	Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. <i>Gynecologic Oncology</i> , 2020, 159, 442-448.	0.6	28
8	Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. <i>Gynecologic Oncology</i> , 2019, 152, 235-242.	0.6	10
9	Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. <i>Supportive Care in Cancer</i> , 2019, 27, 2699-2705.	1.0	11
10	Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study. <i>Drugs - Real World Outcomes</i> , 2018, 5, 225-235.	0.7	8
11	Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant. <i>Annals of Oncology</i> , 2017, 28, 1268-1273.	0.6	7
12	MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update. <i>Supportive Care in Cancer</i> , 2017, 25, 267-269.	1.0	19
13	Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. <i>European Journal of Cancer</i> , 2016, 66, 114-124.	1.3	16
14	2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Annals of Oncology</i> , 2016, 27, v119-v133.	0.6	454
15	Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2016, 27, v111-v118.	0.6	454
16	Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study. <i>Annals of Oncology</i> , 2015, 26, 981-986.	0.6	23
17	Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. <i>Annals of Oncology</i> , 2015, 26, v139-v151.	0.6	188
18	Bone health in cancer patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2014, 25, iii124-iii137.	0.6	450

#	ARTICLE	IF	CITATIONS
19	Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. <i>Annals of Oncology</i> , 2014, 25, 1492-1499.	0.6	240
20	Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. <i>British Journal of Cancer</i> , 2012, 106, 1353-1360.	2.9	222
21	Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. <i>Journal of Geriatric Oncology</i> , 2012, 3, 33-40.	0.5	58
22	Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis. <i>Annals of Oncology</i> , 2009, 20, iv156-iv158.	0.6	34
23	A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 1BA5510-1BA5510.	0.8	0
24	Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. <i>Supportive Care in Cancer</i> , 2007, 15, 417-426.	1.0	18
25	Ondansetron Plus Metopimazine Compared With Ondansetron Plus Metopimazine Plus Prednisolone as Antiemetic Prophylaxis in Patients Receiving Multiple Cycles of Moderately Emetogenic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2091-2097.	0.8	42
26	Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1690-1696.	0.8	30
27	Dose-finding study of oral metopimazine. <i>Supportive Care in Cancer</i> , 1997, 5, 38-43.	1.0	12
28	Bioavailability of the antiemetic metopimazine given as a microenema. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 613-615.	1.1	8
29	Development of Antiemetic Therapy in Cancer Patients. <i>Acta Oncologica</i> , 1995, 34, 637-640.	0.8	9
30	We still need common criteria for the assessment of nausea and vomiting. <i>European Journal of Cancer</i> , 1994, 30, 1217.	1.3	2
31	Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D ₂ , 5-hydroxytryptamine ₃ , histamine H ₁ , muscarine cholinergic and ? ₁ receptors. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 53-56.	1.1	21
32	Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic Chemotherapy. <i>New England Journal of Medicine</i> , 1993, 328, 1076-1080.	13.9	84
33	Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. <i>European Journal of Cancer</i> , 1992, 28, 1070-1073.	1.3	12
34	High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. <i>Annals of Oncology</i> , 1991, 2, 223-227.	0.6	8
35	The effect of food on serum concentrations of metopimazine.. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 237-243.	1.1	12